In the glioma tissue microarray cohort, the protein expression of PDCL3 in WHO II grades was significantly lower than that in WHO III and WHO IV grades (Figure 2L), and patients with lower PDCL3 protein expression had a better prognosis (Figure 2M). This evidence concerns the gene PDCL3 and central nervous system cancer.